{"analyses":[{"ciLowerLimit":"0.872","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.015","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Geometric mean ratio","paramValue":"0.941"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.66","value":"250.63"},{"groupId":"OG001","spread":"31.45","value":"236.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \\[up to 26 months\\])","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle of rituximab IV (375 mg/m\\^2) + 7 cycles of rituximab subcutaneously (SC) (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Stage 1 PK Evaluable Population. Here, number of participants analyzed = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Stage I (Induction): Predose (within 2hr) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)","title":"Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}